Target intelligence / Profile preview

Gas–liquid interface in the intestinal lumen

Molecular classification
Physical interface, Physicochemical target
01

Overview

The gas–liquid interface in the intestinal lumen is the physical boundary where gastrointestinal gases, such as nitrogen, hydrogen, and carbon dioxide, meet the liquid mucus and chyme within the digestive tract (StatPearls, 2023). Under normal physiological conditions, gas is passed efficiently; however, in various gastrointestinal disorders, gas can become trapped in a stable, fine foam, leading to clinical symptoms like bloating, distension, and abdominal pain (PubMed, PMID: 24106601). This interface acts as a physicochemical target for anti-foaming agents, most notably simethicone, which is a mixture of polydimethylsiloxane and silica gel (PubChem, CID: 6433516). These drugs do not interact with traditional biological receptors or enzymes but instead lower the surface tension at the gas-liquid boundary, causing small, trapped bubbles to coalesce into larger ones that are more easily eliminated via eructation or flatulence (DrugBank, DB09512). Targeting this interface is a standard approach for the symptomatic treatment of functional dyspepsia, irritable bowel syndrome, and postoperative gas distress. Additionally, modifying this interface is clinically significant for improving mucosal visualization during diagnostic procedures like endoscopy or ultrasound by removing obscuring foam (NIH, 2022).

Other names
Intestinal gas bubblesGastrointestinal gas-liquid interfaceIntestinal foamGas-mucus interface
02

Mechanism of action

Reduction of surface tension at the gas-liquid interface, facilitating the coalescence of small, trapped bubbles into larger ones that are more easily expelled via eructation or flatus (StatPearls, 2023).

03

Biological functions

Gas transportDigestionSurface tension regulation
04

Disease associations

FlatulenceAbdominal bloatingFunctional dyspepsiaIrritable bowel syndromePostoperative gas pain
05

Safety considerations

Potential for reduced absorption of co-administered medications (e.g., levothyroxine) (StatPearls, 2023)Masking of underlying mechanical bowel obstructionHypersensitivity reactions (rare)
06

Interacting drugs

Simethicone

1 more in the full profile.

07

Biomarkers

Reduction in abdominal girthFrequency of flatusEndoscopic bubble scoreAbdominal ultrasound clarity

Beyond the preview

Go deeper on Gas–liquid interface in the intestinal lumen.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gas–liquid interface in the intestinal lumen.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call